Novartis's Lucentis wins diabetic macular oedema indication in EU
This article was originally published in Scrip
Executive Summary
The European Commission has approved a new indication for Novartis's VEGF receptor antagonist Lucentis (ranibizumab) for vision loss caused by diabetic macular oedema (DMO), said the firm today.